Reply  by Mell, Matthew
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 4 Letters to the Editor 1121criteria used for native arteries. The criteria used in COBEST have
not been validated for diagnosis of restenosis after iliac artery stent-
ing or stent grafting. No data are provided as to the distribution of
the diagnostic modalities used to diagnose the stenoses in COB-
EST, nor do the authors provide data on how many patients had
conﬁrmation of the restenosis by angiography.
Finally, COBEST did not stratify patients on the basis of the
TransAtlantic Inter-Society Consensus (TASC) classiﬁcation, and
more than 60% of the patients had TASC B disease. Therefore,
the study is underpowered to make any meaningful conclusion
for the post hoc analysis of patients with TASC C and D disease
where the authors indicated a difference in binary restenosis
between the two stents.
Our study and COBEST have clearly sparked interest.
The DISCOVER6 trial will use some of the same end points as
COBEST and will be underpowered for subgroup analyses. On
the other hand, the planned assessment of quality of life and
walking scores may help determine whether restenosis is an
outcome that is important to patients.
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Regarding “Interfacility transfer and mortality
for patients with ruptured abdominal aortic
aneurysm”
We were pleased to read the systematic analysis concerning
interfacility transfer and mortality for patients with ruptured
abdominal aortic aneurysm (rAAA) by Mell et al.1 We do disagree,
however, with the ﬁrst part of the discussion stating that their
actual study was the ﬁrst to describe population-level outcomes
for patients with rAAAs, including patients transferred for care.
Our analysis,2 published in 2012, is based on the entire populationof Norway and describes incidence, handling, and outcome for pa-
tients with rAAA in Norway, including those transferred to
another hospital before operative repair.
Interestingly, the proportions of patients transferred for treat-
ment of rAAA, as well as the proportions of patients who under-
went rAAA repair after transfer, are similar in both studies. The
former is 19.1% in their study compared with 17.9% (87 of 487)
in our study, the latter is 83.3% (706 of 847) in their study
compared with 86.2% (75 of 87) in our study.1,2
Both studies indicate that most patients with rAAA can still be
treated after transfer, which is good news, bearing in mind that
centralization of vascular services leaves transfer and a subsequent
operation as the only treatment option for a growing number of
patients. Optimizing transfer time and communication between
hospitals, including shared imaging, enabling preoperative prepara-
tion before the patient arrives, may improve results to a certain de-
gree. Nevertheless, there can be no doubt that screening for AAA
and elective operation will give much better results than even the
most efﬁcient transfer system for patients with rAAA and should be
implemented as soon as possible.3-5 The screening algorithm, how-
ever, may have to be adapted due to changing epidemiology.6
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Reply
Our study is the ﬁrst to describe population level outcomes in
the United States, and we appreciate the references provided by Dr
Altreuther describing a European experience. It is noteworthy that
the ﬁndings of both studies are quite similar, despite differences in
health care delivery systems, geography, and distances. We also
agree that the best treatment for ruptured abdominal aortic aneu-
rysm (rAAA) is prevention, with early detection and effective sur-
veillance.1,2 For those who present with rAAA and cannot receive
treatment at the initial presenting facility, we found that the ben-
eﬁts of transfer for repair appear to be eclipsed by those who die
en route or after arrival to the receiving hospital without receiving
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1122 Letters to the Editor October 2014repair. The latter perhaps may be due to patient preference, clinical
deterioration, or severe comorbid conditions that preclude survival
even with attempted repair.
We believe that the transfer process for rAAA can be improved
to ensure optimal outcomes with efﬁcient utilization of resources.
Potential strategies include improvements in the transfer process,
as outlined by Dr Altreuther, as well as improved guidelines to
identify patients whose survival is unlikely and for whom care mea-
sures other than transfer may be considered.
Matthew Mell, MD
Division of Vascular Surgery
Stanford University
Stanford, Calif
REFERENCES
1. Shreibati JB, Baker LC, Hlatky MA, Mell MW. Impact of the Screening
Abdominal Aortic Aneurysms Very Efﬁciently (SAAAVE) Act on
abdominal ultrasonography use among Medicare beneﬁciaries. Arch
Intern Med 2012;172:1456-62.
2. Mell MW, Baker LC, Dalman RL, Hlatky MA. Gaps in preoperative
surveillance and rupture of abdominal aortic aneurysms among Medicare
beneﬁciaries. J Vasc Surg 2014;59:583-8.
http://dx.doi.org/10.1016/j.jvs.2014.06.111
Regarding “Prospective, randomized study of cutting
balloon angioplasty versus conventional balloon
angioplasty for the treatment of hemodialysis access
stenoses”
In their recently reported randomized trial, Saleh et al found
that cutting balloon angioplasty improved treatment area pri-
mary patency of graft-vein anastomotic lesions at 6 and 12
months compared with conventional balloon angioplasty.1 How-
ever, for lesions at other locations treated with cutting balloons,
there was no beneﬁt over conventional angioplasty. We believe
the study has several important limitations that require further
discussion.
The study included both native arteriovenous ﬁstulas (AVFs)
and prosthetic grafts, but it is well established that prosthetic grafts
require more interventions to maintain patency than AVFs do.2
These two scenarios have vastly differing pathologic processes
and outcomes and cannot be grouped as if similar. Reporting
the proportion of native AVFs and grafts in the study and sub-
group analysis separating both types of access would provide addi-
tional important information.
Saleh et al classify lesion location into four categories:
venous, graft-to-vein anastomotic, intragraft, and arterial anasto-
motic. In native AVFs, only two of these categories apply. In such
cases, venous refers to all lesions from the arteriovenous anasto-
mosis to the cephalic arch. The terminal portion of the cephalic
vein is particularly prone to restenosis after conventional angio-
plasty and is, in and of itself, an area of research interest. Obser-
vational studies also suggest that lesion length and angioplasty in
newer AVFs may also be associated with higher rates of resteno-
sis.3 Information on access age, lesion characteristics, and com-
parison of patency at other speciﬁc venous locations might
generate additional hypotheses on the indications for cutting
balloon use.
Cumulative or secondary patency (ie, the time from initial
angioplasty until the access is abandoned) is the most important
outcome for patients as it represents the functional life of the ac-
cess. However, the authors do not report this outcome; instead,
the main patency deﬁnition used is treatment area primary
patency. Reporting access circuit primary patency (ie, the time
from initial angioplasty to repeated endovascular intervention
for any lesion in the access circuit) is mandatory and ultimately
more important than isolated lesion primary patency. Thrombosisleading to access loss is important because of the potential for
exposure of the patient to mortality risk associated with central
venous catheters. Freedom from access interventions is another
important measure of quality of life for hemodialysis patients.
None of these clinically meaningful end points are measured or
reported in the trial.
This study is timely, given the increasingly strong evidence sup-
porting the use of stent grafts in many of these scenarios, such as the
original FLAIR trial and presented results of REVISE and REN-
OVA, all randomized trials demonstrating graft preservation supe-
rior to angioplasty to 2 years.4 One other recent study, by Aftab
et al, suggested the utility of cutting balloon compared with angio-
plasty in AVFs,5 although Vesely and Siegel’s larger trial in pros-
thetic grafts did not.6 Given these mixed messages and limits of
presented data within the current study, we believe that the study
by Saleh et al does not support the widespread use of cutting
balloon angioplasty for dialysis access stenosis.
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Regarding “Management of acute limb ischemia in the
pediatric population”
Peripheral vascular injuries of the lower extremity in the pedi-
atric population are rare but can result in signiﬁcant morbidity.
These injuries are usually iatrogenic after catheterization or inva-
sive monitoring. Pediatric peripheral vascular trauma is far less
frequent, and there is scarcity of reported experience with
